LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 461

Search options

  1. Book ; Online: Event Classification with Multi-step Machine Learning

    Saito, Masahiko / Kishimoto, Tomoe / Kaneta, Yuya / Itoh, Taichi / Umeda, Yoshiaki / Tanaka, Junichi / Iiyama, Yutaro / Sawada, Ryu / Terashi, Koji

    2021  

    Abstract: The usefulness and value of Multi-step Machine Learning (ML), where a task is organized into connected sub-tasks with known intermediate inference goals, as opposed to a single large model learned end-to-end without intermediate sub-tasks, is presented. ... ...

    Abstract The usefulness and value of Multi-step Machine Learning (ML), where a task is organized into connected sub-tasks with known intermediate inference goals, as opposed to a single large model learned end-to-end without intermediate sub-tasks, is presented. Pre-optimized ML models are connected and better performance is obtained by re-optimizing the connected one. The selection of an ML model from several small ML model candidates for each sub-task has been performed by using the idea based on Neural Architecture Search (NAS). In this paper, Differentiable Architecture Search (DARTS) and Single Path One-Shot NAS (SPOS-NAS) are tested, where the construction of loss functions is improved to keep all ML models smoothly learning. Using DARTS and SPOS-NAS as an optimization and selection as well as the connections for multi-step machine learning systems, we find that (1) such a system can quickly and successfully select highly performant model combinations, and (2) the selected models are consistent with baseline algorithms, such as grid search, and their outputs are well controlled.
    Keywords Computer Science - Machine Learning
    Subject code 006
    Publishing date 2021-06-04
    Publishing country us
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article: Fatal pulmonary infection due to multidrug-resistant Mycobacterium kansasii which developed in an immunocompetent young man.

    Yamada, H / Kohyama, T / Terashi, K / Mori, H / Yamaguchi, A / Arima, N / Tanaka, H

    Internal medicine (Tokyo, Japan)

    1997  Volume 36, Issue 4, Page(s) 298–300

    Abstract: A 32-year-old immunocompetent man developed fever and malaise that persisted for three years. As he had no health insurance, he never received any medical treatment. On admission, chest X-ray revealed multiple cavitary lesions and his sputnum yielded ... ...

    Abstract A 32-year-old immunocompetent man developed fever and malaise that persisted for three years. As he had no health insurance, he never received any medical treatment. On admission, chest X-ray revealed multiple cavitary lesions and his sputnum yielded acid-fast bacilli, that were identified as Mycobacterium kansasii with multidrug resistance. Although his general status improved transiently by antituberculous agents, he died of respiratory insufficiency after four months. The prognosis of Mycobacterium kansasii pulmonary disease is reported to be relatively good among non-tuberculous mycobacteriosis, however, physicians must pay careful attention to cases of delayed start of therapy or multidrug resistance, or both.
    MeSH term(s) Adult ; Antitubercular Agents/pharmacology ; Drug Resistance, Multiple ; Fatal Outcome ; Humans ; Immunocompetence ; Male ; Mycobacterium Infections, Nontuberculous/etiology ; Nontuberculous Mycobacteria/drug effects ; Prognosis ; Respiratory Insufficiency/etiology ; Tuberculosis, Multidrug-Resistant/etiology ; Tuberculosis, Pulmonary/etiology
    Chemical Substances Antitubercular Agents
    Language English
    Publishing date 1997-04
    Publishing country Japan
    Document type Case Reports ; Journal Article
    ZDB-ID 32371-8
    ISSN 0918-2918 ; 0021-5120
    ISSN 0918-2918 ; 0021-5120
    DOI 10.2169/internalmedicine.36.298
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Effects of renal function on pharmacokinetics of recombinant human granulocyte colony-stimulating factor in lung cancer patients.

    Fukuda, M / Oka, M / Ishida, Y / Kinoshita, H / Terashi, K / Kawabata, S / Kinoshita, A / Soda, H / Kohno, S

    Antimicrobial agents and chemotherapy

    2001  Volume 45, Issue 7, Page(s) 1947–1951

    Abstract: Animal studies suggest that the kidney is involved in the elimination of recombinant human granulocyte colony-stimulating factor (rhG-CSF), which is used for patients with neutropenia during cancer chemotherapy. Since anticancer drugs induce ... ...

    Abstract Animal studies suggest that the kidney is involved in the elimination of recombinant human granulocyte colony-stimulating factor (rhG-CSF), which is used for patients with neutropenia during cancer chemotherapy. Since anticancer drugs induce nephrotoxicity, it is important to clarify the role of the kidney in the pharmacokinetics of rhG-CSF in cancer patients. Our study was designed to evaluate the relationship between the pharmacokinetics of rhG-CSF and renal function in lung cancer patients compared to the absolute neutrophil count (ANC). The pharmacokinetic studies were conducted with 25 lung cancer patients. Following chemotherapy using platinum-based compounds, a bolus 5 microg of rhG-CSF/kg of body weight was intravenously injected from the first day of leukopenia or neutropenia. Pharmacokinetic parameters were estimated by fitting the concentration in serum-time data to a two-compartment model according to the population pharmacokinetics and the Bayesian method. Creatinine clearance (CL(CR)) was predicted by the Cockcroft-Gault formula. rhG-CSF clearance (CL(G-CSF)) correlated significantly with the ANC (r = 0.613; P < 0.001) and CL(CR) (r = 0.632; P < 0.001). Multiple linear regression analysis showed that the combination of the ANC and CL(CR) accounted for 57.4% of the variation of CL(G-CSF). In patients with an ANC of <1,000/microl, CL(CR) accounted for 72.9% of the variation of CL(G-CSF) (P < 0.001). Our findings suggest that renal function and neutrophil counts correlate with CL(G-CSF) and that the role of renal function in eliminating rhG-CSF is important in lung cancer patients with neutropenia.
    MeSH term(s) Adult ; Aged ; Female ; Granulocyte Colony-Stimulating Factor/pharmacokinetics ; Humans ; Kidney/metabolism ; Kidney Function Tests ; Lung Neoplasms/metabolism ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Recombinant Proteins/pharmacokinetics
    Chemical Substances Recombinant Proteins ; Granulocyte Colony-Stimulating Factor (143011-72-7)
    Language English
    Publishing date 2001-07
    Publishing country United States
    Document type Clinical Trial ; Controlled Clinical Trial ; Journal Article
    ZDB-ID 217602-6
    ISSN 1098-6596 ; 0066-4804
    ISSN (online) 1098-6596
    ISSN 0066-4804
    DOI 10.1128/AAC.45.7.1947-1951.2001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis.

    Saotome, T / Minoura, S / Terashi, K / Sato, T / Echizen, H / Ishizaki, T

    Journal of clinical pharmacology

    1993  Volume 33, Issue 10, Page(s) 979–988

    Abstract: The hypotensive effect, kinetics, and concentration-response relationship of labetalol, alpha beta- and alpha 1-adrenoceptor blocking drug, were studied in seven women with a moderate-to-severe hypertension (averaged diastolic blood pressure [DBP] of 100 ...

    Abstract The hypotensive effect, kinetics, and concentration-response relationship of labetalol, alpha beta- and alpha 1-adrenoceptor blocking drug, were studied in seven women with a moderate-to-severe hypertension (averaged diastolic blood pressure [DBP] of 100 to 120 mm Hg measured during a 1- to 2-day hospitalization period) during the third trimester of pregnancy who received the oral twice-daily doses of 150 to 450 mg. These dosages were individually selected by attaining a therapeutic goal of DBP < or = 100 mm Hg or systolic blood pressure (SBP)/DBP reduction of > 30/15 mm Hg, as compared with the pretreatment value, at any time during the 12-hour dosing interval for a 3- to 5-day dosage escalation period. Labetalol concentrations in plasma were measured by a high-performance liquid chromatography with fluorescence detection, and the plasma drug concentration-response relationship was analyzed by a sigmoidal Emax model. Labetalol decreased significantly (P < 0.05 to 0.01) the pretreatment SBP/DBP (166.3 +/- 5.2/110.3 +/- 3.0 mm Hg, mean +/- SEM) without any recognizable side-effects during the twice-daily dosing period in the mothers. Peaked concentrations occurred at 1 hour postdose in all patients. The elimination half-lives ranged from 4.3 to 6.9 hours, and the apparent oral clearance from 31.9 to 73.3 mL/min/kg. The pharmacodynamic parameters (Emax and EC50) analyzed by the Emax model revealed a 3- to 5-fold interindividual variability. The gestational ages at delivery ranged from 34 to 37 weeks, and the birth weights were < 2000 g in 6 of the 7 neonates. Four neonates developed respiratory distress syndrome after delivery, and one infant died of pulmonary hypoplasia 3 months later. The results indicate that 1) labetalol orally administered in a twice-daily regimen as done in this study is an effective antihypertensive drug in women with hypertension during late pregnancy, and 2) interindividual variability in the kinetic factor (e.g., oral clearance) as well as that in the pharmacodynamic factor (e.g., EC50) appear to be related to the overall variability in the hypotensive responsiveness to the drug. However, whether labetalol and/or hypertension per se would have been related to the fetal outcome remains unanswered from the present study.
    MeSH term(s) Adult ; Apgar Score ; Birth Weight ; Blood Pressure/drug effects ; Drug Administration Schedule ; Female ; Gestational Age ; Humans ; Hypertension/drug therapy ; Hypertension/metabolism ; Hypertension/physiopathology ; Infant, Newborn ; Labetalol/administration & dosage ; Labetalol/pharmacokinetics ; Labetalol/therapeutic use ; Metabolic Clearance Rate ; Pregnancy ; Pregnancy Complications, Cardiovascular/drug therapy ; Pregnancy Complications, Cardiovascular/metabolism ; Pregnancy Complications, Cardiovascular/physiopathology ; Pregnancy Outcome ; Pregnancy Trimester, Third ; Respiratory Distress Syndrome, Newborn/complications ; Respiratory Distress Syndrome, Newborn/metabolism
    Chemical Substances Labetalol (R5H8897N95)
    Language English
    Publishing date 1993-10
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 188980-1
    ISSN 1552-4604 ; 0091-2700 ; 0021-9754
    ISSN (online) 1552-4604
    ISSN 0091-2700 ; 0021-9754
    DOI 10.1002/j.1552-4604.1993.tb01933.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients.

    Terashi, K / Oka, M / Ohdo, S / Furukubo, T / Ikeda, C / Fukuda, M / Soda, H / Higuchi, S / Kohno, S

    Antimicrobial agents and chemotherapy

    1999  Volume 43, Issue 1, Page(s) 21–24

    Abstract: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is used to counter chemotherapy-induced neutropenia. Our previous study showed an inverse correlation between serum rhG-CSF levels and the number of circulating neutrophils in cancer ... ...

    Abstract Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is used to counter chemotherapy-induced neutropenia. Our previous study showed an inverse correlation between serum rhG-CSF levels and the number of circulating neutrophils in cancer patients (H. Takatani, H. Soda, M. Fukuda, M. Watanabe, A. Kinoshita, T. Nakamura, and M. Oka, Antimicrob. Agents Chemother. 40:988-991, 1996). The aim of this study was to clarify the relationship between rhG-CSF clearance and G-CSF receptors on circulating neutrophils. In five cancer patients receiving chemotherapy, a bolus dose of rhG-CSF (5 microg/kg) was injected intravenously during defined phases of posttreatment neutropenia and neutrophilia. Serum rhG-CSF levels were measured by a chemiluminescence enzyme immunoassay and analyzed by moment analysis. G-CSF receptors on neutrophils were detected by flow cytometry with biotinylated rhG-CSF. rhG-CSF clearance was significantly higher at neutrophilia than at neutropenia (1,497 +/- 132 versus 995 +/- 266 ml/h; P < 0.01). The percentage of G-CSF receptor-positive neutrophils, reflecting the number of G-CSF receptors per cell, was low at neutropenia without rhG-CSF therapy (44.5% +/- 22.1%) and high at neutrophilia with rhG-CSF therapy (73. 0% +/- 11.4%; P < 0.01). rhG-CSF clearance closely correlated with the percentage of G-CSF receptor-positive neutrophils (r2 = 0.91; P < 0.0001) and neutrophil count (r2 = 0.72; P < 0.005). Our results indicate that, in cancer patients receiving chemotherapy, rhG-CSF increases the number of G-CSF receptors per cell as well as circulating neutrophil counts, resulting in modulation of its own clearance.
    MeSH term(s) Adjuvants, Immunologic/administration & dosage ; Adjuvants, Immunologic/pharmacokinetics ; Adjuvants, Immunologic/pharmacology ; Aged ; Aged, 80 and over ; Female ; Flow Cytometry ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Granulocyte Colony-Stimulating Factor/pharmacokinetics ; Granulocyte Colony-Stimulating Factor/pharmacology ; Humans ; Injections, Intravenous ; Lenograstim ; Lung Neoplasms/blood ; Male ; Middle Aged ; Neutrophils/drug effects ; Neutrophils/metabolism ; Ovarian Neoplasms/blood ; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/drug effects ; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/metabolism ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/pharmacokinetics ; Recombinant Proteins/pharmacology
    Chemical Substances Adjuvants, Immunologic ; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor ; Recombinant Proteins ; Granulocyte Colony-Stimulating Factor (143011-72-7) ; Lenograstim (6WS4C399GB)
    Language English
    Publishing date 1999-01
    Publishing country United States
    Document type Clinical Trial ; Journal Article
    ZDB-ID 217602-6
    ISSN 1098-6596 ; 0066-4804
    ISSN (online) 1098-6596
    ISSN 0066-4804
    DOI 10.1128/AAC.43.1.21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: A leukotriene receptor antagonist, ONO-1078, modulates drug sensitivity and leukotriene C4 efflux in lung cancer cells expressing multidrug resistance protein.

    Nakano, R / Oka, M / Nakamura, T / Fukuda, M / Kawabata, S / Terashi, K / Tsukamoto, K / Noguchi, Y / Soda, H / Kohno, S

    Biochemical and biophysical research communications

    1998  Volume 251, Issue 1, Page(s) 307–312

    Abstract: ONO-1078 is a new class of peptide leukotriene receptor antagonist, and multidrug resistance protein (MRP) is a membrane tranporter of multiple anticancer drugs and endogenous leukotriene C4 (LTC4). We investigated the effects of ONO-1078 on drug ... ...

    Abstract ONO-1078 is a new class of peptide leukotriene receptor antagonist, and multidrug resistance protein (MRP) is a membrane tranporter of multiple anticancer drugs and endogenous leukotriene C4 (LTC4). We investigated the effects of ONO-1078 on drug sensitivity and LTC4-efflux in MRP-expressing lung cancer cells. Drug sensitivity, intracellular vincristine accumulation, and intracellular and extracellular LTC4 concentrations were measured with or without ONO-1078. The effect of ONO-1078 on MRP-mediated calcein-efflux was determined by flow cytometry. ONO-1078 (1 to 10 microM) dose-dependently enhanced the sensitivity of NCI-H520 cells to vincristine with the reduced accumulation, and also enhanced the sensitivity to doxorubicin and etoposide. ONO-1078 inhibited both LTC4- and calcein-efflux from the cells with increased intracellular accumulations. Our findings indicate that ONO-1078 modulates multidrug resistance and inhibits LTC4-efflux in lung cancer cells, by inhibition of MRP function.
    MeSH term(s) ATP-Binding Cassette Transporters/biosynthesis ; Adenocarcinoma/metabolism ; Carcinoma, Squamous Cell/metabolism ; Chromones/pharmacology ; Dose-Response Relationship, Drug ; Drug Resistance, Multiple ; Flow Cytometry ; Fluoresceins/metabolism ; Fluorescent Dyes/metabolism ; Humans ; Leukotriene Antagonists/pharmacology ; Leukotriene C4/antagonists & inhibitors ; Leukotriene C4/metabolism ; Lung Neoplasms/metabolism ; Multidrug Resistance-Associated Proteins ; Tumor Cells, Cultured ; Vincristine/metabolism
    Chemical Substances Chromones ; Fluoresceins ; Fluorescent Dyes ; Leukotriene Antagonists ; Multidrug Resistance-Associated Proteins ; Leukotriene C4 (2CU6TT9V48) ; Vincristine (5J49Q6B70F) ; pranlukast (TB8Z891092) ; fluorexon (V0YM2B16TS)
    Language English
    Publishing date 1998-10-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 205723-2
    ISSN 0006-291X ; 0006-291X
    ISSN (online) 0006-291X
    ISSN 0006-291X
    DOI 10.1006/bbrc.1998.9472
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: [Diseases associated with glucagon autoantibodies].

    Baba, S / Morita, S / Kobayashi, N / Terashi, K

    Horumon to rinsho. Clinical endocrinology

    1978  Volume 26, Issue 7, Page(s) 653–659

    MeSH term(s) Adult ; Aged ; Autoantibodies/analysis ; Child ; Child, Preschool ; Diabetes Mellitus/immunology ; Female ; Glucagon/immunology ; Humans ; Infant, Newborn ; Male ; Middle Aged
    Chemical Substances Autoantibodies ; Glucagon (9007-92-5)
    Language Japanese
    Publishing date 1978-07
    Publishing country Japan
    Document type Case Reports ; Journal Article
    ZDB-ID 603692-2
    ISSN 0045-7167 ; 0439-5875
    ISSN 0045-7167 ; 0439-5875
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Multidrug resistance-associated protein gene expression and drug sensitivity in human lung cancer cells.

    Narasaki, F / Oka, M / Fukuda, M / Ikeda, K / Terashi, K / Takatani, H / Nakamura, T / Soda, H / Kohno, S

    Anticancer research

    1997  Volume 17, Issue 5A, Page(s) 3493–3497

    Abstract: Multidrug resistance-associated protein (MRP) mRNA expression and drug sensitivity in lung cancer cells were examined, and the effects of verapamil, a modulating agent for MRP, on drug sensitivity were also tested. Nine cell lines expressed various ... ...

    Abstract Multidrug resistance-associated protein (MRP) mRNA expression and drug sensitivity in lung cancer cells were examined, and the effects of verapamil, a modulating agent for MRP, on drug sensitivity were also tested. Nine cell lines expressed various levels of MRP gene expression but not the MDR1 gene. The levels were higher in non-small cell carcinoma cells (NSCLC) than in small cell carcinoma cells (SCLC). Clear correlations between the MRP gene level and the sensitivity to etoposide (VP-16) and doxorubicin (Dox) were observed except for one cell line which highly expressed DNA topoisomerase II. Positive correlations between the MRP gene levels in three cell lines and the modulation effects of verapamil in VP-16, Dox, and vincristine were observed. The present results indicate that MRP probably confers intrinsic multidrug resistance in NSCLC rather than in SCLC.
    MeSH term(s) ATP-Binding Cassette Transporters/genetics ; Cisplatin/pharmacology ; Doxorubicin/pharmacology ; Drug Resistance, Multiple ; Etoposide/pharmacology ; Gene Expression Regulation, Neoplastic/genetics ; Genes, MDR ; Humans ; Lung Neoplasms ; Multidrug Resistance-Associated Proteins ; RNA, Messenger/genetics ; Tumor Cells, Cultured/drug effects ; Verapamil/pharmacology ; Vincristine/pharmacology
    Chemical Substances Multidrug Resistance-Associated Proteins ; RNA, Messenger ; Vincristine (5J49Q6B70F) ; Etoposide (6PLQ3CP4P3) ; Doxorubicin (80168379AG) ; Verapamil (CJ0O37KU29) ; Cisplatin (Q20Q21Q62J)
    Language English
    Publishing date 1997-09
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: [Ifosfamide chemotherapy ineffective for advanced pancreatic carcinoma].

    Fujiki, T / Futatsuki, K / Akazawa, S / Yamamoto, K / Kanda, Y / Yamato, A / Terashi, K / Suda, Y

    Gan to kagaku ryoho. Cancer & chemotherapy

    1997  Volume 24, Issue 5, Page(s) 569–572

    Abstract: Ifosfamide chemotherapy was studied in 20 patients with advanced pancreatic carcinoma. It was administered at a dose of 1.2-1.5 g/body/day for 5 consecutive days every 3-4 weeks, and the patients treated over 2 courses were registered in our trial. ... ...

    Abstract Ifosfamide chemotherapy was studied in 20 patients with advanced pancreatic carcinoma. It was administered at a dose of 1.2-1.5 g/body/day for 5 consecutive days every 3-4 weeks, and the patients treated over 2 courses were registered in our trial. Eleven patients had not received prior chemotherapy. Results achieved were as follows: PR in one patient, NC in 9 patients, and PD in 10 patients. The response rate was 5% and the median survival time was 17 weeks. Toxic effects included anorexia (80%), nausea and vomiting (65%), alopecia (20%), mental disturbance (20%), granulocytopenia (20%), thrombocytopenia (5%), and no renalurological disturbance. We concluded that ifosfamide was not effective for chemotherapy of advanced pancreatic carcinoma.
    MeSH term(s) Adult ; Aged ; Anorexia/chemically induced ; Antineoplastic Agents, Alkylating/adverse effects ; Antineoplastic Agents, Alkylating/therapeutic use ; Drug Administration Schedule ; Female ; Humans ; Ifosfamide/adverse effects ; Ifosfamide/therapeutic use ; Male ; Middle Aged ; Nausea/chemically induced ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/mortality ; Survival Analysis ; Vomiting/chemically induced
    Chemical Substances Antineoplastic Agents, Alkylating ; Ifosfamide (UM20QQM95Y)
    Language Japanese
    Publishing date 1997-03
    Publishing country Japan
    Document type English Abstract ; Journal Article
    ZDB-ID 604842-0
    ISSN 0385-0684
    ISSN 0385-0684
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: [Primary pulmonary non-Hodgkin's lymphoma in a patient with dermatomyositis].

    Mori, H / Yamada, H / Terashi, K / Kohyama, T / Kawamata, N / Yamaguchi, A / Arima, N / Tanaka, H

    Nihon Kyobu Shikkan Gakkai zasshi

    1997  Volume 35, Issue 7, Page(s) 807–812

    Abstract: A 47-year-old man with dermatomyositis and interstitial pneumonia had been treated with prednisolone since May, 1992, and with azathioprine since April, 1993. During the sixth month of this treatment, primary pulmonary non-Hodgkin's lymphoma (T-cell, ... ...

    Abstract A 47-year-old man with dermatomyositis and interstitial pneumonia had been treated with prednisolone since May, 1992, and with azathioprine since April, 1993. During the sixth month of this treatment, primary pulmonary non-Hodgkin's lymphoma (T-cell, diffuse, pleomorphic) developed. Chemotherapy (vincristine and adriamycin) was begun but there was no response. An invasive lesion of the brain was seen on a CT image. Despite cranial radiotherapy, the patient died of respiratory suppression due to progressive brain disease on December 14, 1993. Primary pulmonary non-Hodgkin's lymphoma develops only rarely in patients with dermatomyositis. In this case, oncogenesis may have been related to the use of immunosuppressants.
    MeSH term(s) Azathioprine/adverse effects ; Dermatomyositis/complications ; Dermatomyositis/drug therapy ; Humans ; Immunosuppressive Agents/adverse effects ; Lung Diseases, Interstitial/complications ; Lung Neoplasms/etiology ; Lymphoma, Non-Hodgkin/etiology ; Lymphoma, T-Cell/etiology ; Male ; Middle Aged
    Chemical Substances Immunosuppressive Agents ; Azathioprine (MRK240IY2L)
    Language Japanese
    Publishing date 1997-07
    Publishing country Japan
    Document type Case Reports ; English Abstract ; Journal Article
    ZDB-ID 604106-1
    ISSN 0301-1542
    ISSN 0301-1542
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top